Akari Therapeutics Plc (AKTX) stock
AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.18+0.47 (+7.00%)
Close on Nov 20, 2026Market cap $13.98MP/E –Yield –
Akari Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Akari Therapeutics's shares outstanding was 143.32B at Jun 30, 2026. For fiscal 2025 it was 67.33B, up 181.8% from the year before. Over ten years it grew 54.8% a year on average. The highest annual figure on record is 67.33B in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 67.33B | +181.8% |
| FY2024 | Dec 31, 2024 | 23.89B | +144.0% |
| FY2023 | Dec 31, 2023 | 9.79B | +56.8% |
| FY2022 | Dec 31, 2022 | 6.24B | +45.5% |
| FY2021 | Dec 31, 2021 | 4.29B | +35.9% |
| FY2020 | Dec 31, 2020 | 3.16B | +72.5% |
| FY2019 | Dec 31, 2019 | 1.83B | +18.9% |
| FY2018 | Dec 31, 2018 | 1.54B | +23.5% |
| FY2017 | Dec 31, 2017 | 1.25B | +5.9% |
| FY2016 | Dec 31, 2016 | 1.18B | +38.2% |
| FY2015 | Dec 31, 2015 | 852M | +896.4% |
| FY2014 | Dec 31, 2014 | 86M | -68.8% |
| FY2013 | Dec 31, 2013 | 274M | +69.2% |
| FY2012 | Dec 31, 2012 | 162M | +4.5% |
| FY2011 | Dec 31, 2011 | 155M | +4.4% |
| FY2010 | Dec 31, 2010 | 148M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 143.32B | +127.7% |
| Q1 FY2026 | Mar 31, 2026 | 118.76B | +117.6% |
| Q4 FY2025 | Dec 31, 2025 | 86.41B | +122.6% |
| Q3 FY2025 | Sep 30, 2025 | 65.33B | +167.9% |
| Q2 FY2025 | Jun 30, 2025 | 62.94B | +234.2% |
| Q1 FY2025 | Mar 31, 2025 | 54.59B | +305.8% |
| Q4 FY2024 | Dec 31, 2024 | 38.82B | +341.2% |
| Q3 FY2024 | Sep 30, 2024 | 24.39B | +141.0% |
| Q2 FY2024 | Jun 30, 2024 | 18.84B | +86.2% |
| Q1 FY2024 | Mar 31, 2024 | 13.45B | +77.6% |
| Q4 FY2023 | Dec 31, 2023 | 8.80B | +48.2% |
| Q3 FY2023 | Sep 30, 2023 | 10.12B | +163.0% |
| Q2 FY2023 | Jun 30, 2023 | 10.12B | +284.9% |
| Q1 FY2023 | Mar 31, 2023 | 7.57B | +123.6% |
| Q2 FY2022 | Jun 30, 2022 | 5.93B | +97.7% |
| Q2 FY2021 | Jun 30, 2021 | 3.85B | +52.9% |
| Q4 FY2020 | Dec 31, 2020 | 2.63B | +21.6% |
| Q3 FY2020 | Sep 30, 2020 | 3.39B | +71.8% |
| Q2 FY2020 | Jun 30, 2020 | 3.00B | +86.8% |
| Q1 FY2020 | Mar 31, 2020 | 2.52B | +59.2% |
| Q4 FY2019 | Dec 31, 2019 | 2.16B | +41.6% |
| Q3 FY2019 | Sep 30, 2019 | 1.97B | +67.4% |
| Q2 FY2019 | Jun 30, 2019 | 1.61B | +36.5% |
| Q1 FY2019 | Mar 31, 2019 | 1.58B | +34.2% |
| Q2 FY2018 | Jun 30, 2018 | 1.53B | +29.2% |
| Q2 FY2017 | Jun 30, 2017 | 1.18B | +50.7% |
| Q2 FY2016 | Jun 30, 2016 | 1.18B | +63.0% |
| Q1 FY2016 | Mar 31, 2016 | 1.18B | +63.0% |
| Q4 FY2015 | Dec 31, 2015 | 1.18B | +859.2% |
| Q3 FY2015 | Sep 30, 2015 | 782M | +965.5% |
| Q2 FY2015 | Jun 30, 2015 | 722M | -0.1% |
| Q1 FY2015 | Mar 31, 2015 | 722M | – |
| Q4 FY2014 | Dec 31, 2014 | 123M | – |
| Q3 FY2014 | Sep 30, 2014 | 73M | – |
| Q2 FY2014 | Jun 30, 2014 | 723M | – |
See a number that looks wrong?